eligibility_summary
Eligibility: Inclusion—age >6 months, CD19-positive B cells, KPS >80 with expected survival >1 month, hemoglobin >80 g/L, no contraindications to blood cell collection. Exclusion—other active diseases hindering assessment, uncontrolled infection, HIV, active HBV/HCV, pregnant or breastfeeding, systemic steroids within 1 week, prior failed CAR-T.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: 4SCAR19U universal CD19-specific CAR T cells (biologic, gene‑engineered, off‑the‑shelf). Mechanism: a chimeric antigen receptor redirects T cells to bind CD19 on B-lineage cells, triggering T-cell activation, cytokine release, and perforin/granzyme-mediated cytotoxic killing, leading to depletion of CD19+ B cells. Targets: CD19-expressing malignant B cells (e.g., B-ALL, B-cell lymphomas). Pathways engaged: CAR signaling via CD3ζ/co-stimulation to activate effector T-cell functions and overcome tumor-induced immunosuppression.